Analysis of electrocardiographic data following use of paroxetine in pediatric depression and obsessive-compulsive disorder

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 45, Issue 4, 2006, Pages 422-430

  Krulewicz, Stan ^a   Carpenter, David J ^a   Fong, Regan ^a   Horrigan, Joseph P ^a   Lipschitz, Alan ^a   Perera, Philip ^a   Wagner, Karen Dineen ^b  

^a GLAXOSMITHKLINE   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Electrocardiogram; Major depressive disorder; Obsessive compulsive disorder; Paroxetine; Pediatric

Indexed keywords

IMIPRAMINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR EFFECT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART RATE VARIABILITY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSESSIVE COMPULSIVE DISORDER; PEDIATRICS; PR INTERVAL; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RR INTERVAL; SCREENING; CANADA; MULTICENTER STUDY; UNITED STATES;

ADOLESCENT; CANADA; CHILD; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MULTICENTER STUDIES; OBSESSIVE-COMPULSIVE DISORDER; PAROXETINE; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; UNITED STATES;

EID: 33646337660     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.chi.0000198593.30702.48     Document Type: Article

References (29)

1. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM (2003), What clinicians should know about the QT interval. JAMA 289:2120-2127
2. Boyer WF, Blumhardt CL (1992), The safety profile of paroxetine. J Clin Psychiatry 53(suppl):61-66
3. Byram Karasu T, Gelenberg A, Merriam A, Wang P (2000), Practice Guidelines for the Treatment of Patients With Major Depressive Disorder, 2nd ed., Washington, DC: American Psychiatric Association
4. Catalano G, Catalano MC, Epstein MA, Tsambiras PE (2001), QTc interval prolongation associated with citalopram overdose: a case report and literature review. Clin Neuropharmacol 24:58-162
5. Coupland N, Wilson S, Nutt D (1997), Antidepressant drugs and the cardiovascular system: a comparison of tricyclics and selective serotonin reuptake inhibitors and their relevance for the treatment of psychiatric patients with cardiovascular problems. J Psychopharmacol 11:83-92
6. Edwards JG, Goldie A, Papayanni-Papasthatis S (1989), Effect of paroxetine on the electrocardiogram. Psychopharmacology (Berl) 97:96-98
7. Emslie GJ, Heiligenstein JH, Wagner KD et al. (2002), Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 41:1205-1215
8. Emslie GJ, Wagner KD, Kutcher S et al. (in press), Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry
9. Erfurth A, Loew M, Dobmeier P, Wendler G (1998), ECG changes after paroxetine. 3 case reports. Nervenarzt 69:629-631
10. Francis PD (2002), Effects of psychotropic medications on the pediatric electrocardiogram and recommendations for monitoring. Curr Opin Pediatr 14:224-230
11. Geller DA, Wagner KD, Emslie G et al. (2004), Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 43:1387-1396
12. Giardina EG, Bigger JT, Jr, Glassman AH, Perel JM, Kantor SJ (1979), The electrocardiographic and antiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations. Circulation 60:1045-1052
13. Goodnick PJ, Jerry J, Parra F (2002), Psychotropic drugs and the ECG: focus on the QTc interval. Expert Opin Pharmacother 3:479-498
14. Gorman J, Shear K, Cowley D (1998), Practice Guidelines for the Treatment of Patients With Panic Disorder. Washington, DC: American Psychiatric Association
15. Gutgesell H, Atkins D, Barst R et al.(1999), Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: a statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 99:979-982
16. Harris MG, Benfield P (1995), Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness. Drugs Aging 6:64-84
17. Keller MB, Ryan ND, Strober M et al. (2001), Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 40:762-772
18. Kuhs H, Rudolf GA (1990), Cardiovascular effects of paroxetine. Psychopharmacology (Berl) 102:379-382
19. Lam YW, Gaedigk A, Ereshefsky L, Alfaro CL, Simpson J (2002), CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy 22:1001-1006
20. Liston HL, DeVane CL, Boulton DW, Risch SC, Markowitz JS, Goldman J (2002), Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. J Clin Psychopharmacol 22:169-173
21. Meuleman C, Jourdain P, Bellorini M et al. (2001), Citalopram and torsades de pointes. A case report. Arch Mal Coeur Vaiss 94:1021-1024
22. Ray WA, Meredith S, Thapa PB, Hall K, Murray KT (2004), Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 75:234-241
23. Reinblatt SP, Walkup JT (2005), Psychopharmacologic treatment of pediatric anxiety disorders. Child Adolesc Psychiatr Clin N Am 14:877-908
24. Safer DJ, Zito JM, DosReis S (2003), Concomitant psychotropic medication for youths. Am J Psychiatry 160:438-449
25. Research Unit on Pediatric Psychopharmacology Anxiety Study Group (2001), Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 344:1279-1285
26. U.S. Food and Drug Administration (2003), E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; http://www.fda.gov/ohrms/dockets/98fr/2004d-0377-gdl0001.doc; accessed November 3, 2005
27. Vaswani M, Linda FK, Ramesh S (2003), Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 27:85-102
28. Wagstaff AJ, Cheer SM, Matheson AJ, Ormrod D, Goa KL (2002), Paroxetine: an update of its use in psychiatric disorders in adults. Drugs 62:655-703
29. Wilens TE, Biederman J, March JS et al. (1999), Absence of cardiovascular adverse effects of sertraline in children and adolescents. J Am Acad Child Adolesc Psychiatry 38:573-577